Micrima Ltd (the “Company”), the breast imaging company, is pleased to announce that it has signed a distribution agreement with Hologic Inc., a global leader in women’s health, for the Company’s new radio-wave breast imaging system, MARIA®. Under the terms of the agreement, Hologic will act as the sales and distribution partner for Micrima in Germany, Austria and Switzerland (DACH).
The first installations of MARIA®, which received CE mark approval in 2015, are expected to take place in Germany in the coming months.
Micrima has been working to develop a breast imaging system that can be used frequently from a young age to reduce the number of deaths from breast cancer. MARIA® uses harmless radio-waves, does not require breast compression and is cost effective to use. Trials to date have proven that, as an adjunct to X-ray mammography, it is effective at locating cancers, particularly in the dense tissue associated with younger women. The Company plans to introduce tissue differentiation within the MARIA® scan as it rolls out higher levels of functionality over time.
Roy Johnson, Micrima’s Executive Chairman, said: “This is an exciting step for Micrima as we transition from the product development phase into the market. We are pleased to be working with one of the best recognised global companies in breast imaging, and look forward to launching MARIA® into further new territories.”
Heinz Gerhards, Managing Director of Hologic Medicor DACH, said: “We are excited to be working alongside Micrima in the introduction of this new technology to the wider market.”
Prof Iain Lyburn, Consultant Radiologist, Cheltenham General Hospital, said: “We have been involved in the evaluation of the MARIA® system for some time now and whilst it is currently offered as an adjunct to other imaging modalities, particularly where dense tissue is involved, the technique promises the exciting future ability to distinguish between tissue types. Any imaging modality that can readily give this sort of functional information has the potential to influence many points in the diagnostic and treatment pathways – there could be less need for biopsies and possibly a reduction in over treatment.”